Merck Sharp + Dohme Corp.

Danielle Falcone

David Joseph Guerin

David James Witter

David L Sloman

Jason David Katz

Christopher Francis Thompson

Norman Kong

Mark E Scott

Hongbo Zeng

Christopher J Dinsmore

Xianhai Huang

Kevin J Wilson

Phieng Siliphaivanh

Christopher W Boyce

Umar Faruk Mansoor

Matthew H Daniels

Joseph A Kozlowski

Lei Chen

Peter H Fuller

Kathryn Ann Lipford

Zhixiang Zheng

Yunfeng Bai

Ravi Kurukulasuriya

Yumei Liu

Wei Zhou

Qinglin Pu

Luis E Torres

Salem Fevrier

Brendan O'Boyle

Jason D Brubaker

Jongwon Lim

Joey Lee Methot

Raman Kumar Bakshi

Milana M Maletic

Jianmin Fu

Matthew Lloyd Childers

Ganesh Babu Karunakaran

Hongjun Zhang

Ling Tong

Joshua Close

Yongqi Deng

Alessia Petrocchi

Catherine M White

Christian Fischer

Ron Ferguson

Wei Deng

Corey E Bienstock

Jiaqiang Cai

Michelle Martinez

Elizabeth Helen Kelley

Shuyi Tang

Judson E Richard

Xiaoxing Du

Ronald D Ferguson

Angie R Angeles

Jayanth Thiruvellore Thatai

Luis Torres

Bidhan A Shinkre

Chonggang Wang

Brendan M O'BOYLE

Joshua T Close

Xiandai Huang

Ronald D Ii Ferguson

Ravi Kuruklasuriya

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors

Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application. 

N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors

Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer. 

Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors

Disclosed are the ERK inhibitors of formula (1.0) and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). This invention provides compounds that are ERK inhibitors (i.e., ERK2 inhibitors). This invention also provides a pharmaceutical composition comprising an effective amount of at least one (e.g., 1) compound of formula (1.0) and a pharmaceutically acceptable carrier.

ERK inhibitors

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). 

Growing community of inventors

Brookline, MA, United States of America

Danielle Falcone